How can a stem cell transplant treat severe aplastic anemia?

Question

Hello doctor,

My 33-year-old brother is in urgent need of stem cell transplantation for severe aplastic anemia that has become refractory to immunosuppressive therapy. His condition has worsened significantly over the past two months. His hemoglobin levels rarely rise above 6.5 g/dL despite weekly transfusions. His platelet count remains consistently below 10,000, requiring transfusions every three to four days. His absolute neutrophil count is persistently below 200, leading to recurrent infections despite ongoing prophylactic antimicrobial therapy.

He has undergone two complete courses of antithymocyte globulin (ATG) in combination with Cyclosporine, without achieving a sustained response. A recent bone marrow biopsy showed less than 5% cellularity, with no evidence of transformation to myelodysplastic syndrome (MDS) or leukemia.

The transplant team has identified a 9/10 matched unrelated donor. However, they suggested that a haploidentical transplant using me as the donor, despite being only a half-match, might actually be a preferable option. They discussed different conditioning regimens, including post-transplant cyclophosphamide versus traditional calcineurin inhibitors for graft-versus-host disease (GVHD) prevention, but much of the terminology was difficult to fully understand.

My brother’s quality of life is inferior. He has been hospitalized twice with Aspergillus pneumonia, is suffering from painful mucositis of the mouth and throat (likely fungal), and has developed iron overload from repeated transfusions, which is now impacting his liver function.

Given the urgency of his condition, I would appreciate your guidance on the following:

What are the realistic success rates for stem cell transplantation in patients with severe aplastic anemia who have failed immunosuppressive therapy?
How do outcomes compare between matched unrelated donors and haploidentical donors in this context?
What is the typical timeline for recovery of blood counts following transplantation?
Considering his extensive transfusion history and potential alloimmunization, how high is the risk of graft failure?

Please help.

Thank you.

Answer 1

hi dear

Hi,

Welcome to icliniq.com.

I read your query and can understand your concern.

I hope your brother is recovering and receiving the care he needs. A haploidentical bone marrow transplant (haplo-BMT) is a type of allogeneic stem cell transplant in which the donor is a half-matched (haploidentical) relative, most commonly a parent, child, or sibling who shares at least 50% of the patient's human leukocyte antigen (HLA) markers.

Haploidentical transplantation plays a critical role in the following situations:

When a fully HLA-matched sibling donor is not available, which is the case for approximately 70 % of patients.
When an unrelated matched donor cannot be located quickly, particularly in patients from ethnically diverse or underrepresented populations.
When there is an urgent need for transplantation, such as in aggressive or relapsed, or refractory blood cancers.
This approach greatly expands the potential donor pool, improves accessibility, and reduces the time to transplant, which can be vital in life-threatening conditions.

Comparison between haploidentical and matched unrelated donor (MUD) transplants:

Haploidentical donors are often readily available within the immediate family, which enables faster transplantation and easier coordination. In contrast, matched unrelated donors typically require a time-consuming search through international donor registries and may not always be found, especially for patients with uncommon HLA types.
In terms of donor compatibility, haploidentical transplants involve a 50% HLA match, whereas unrelated donors generally offer a full 100% match (10 out of 10 HLA markers). Historically, the risk of graft-versus-host disease (GVHD- a serious complication that can occur after a stem cell or bone marrow transplant) was higher with haploidentical transplantation. However, the introduction of post-transplant cyclophosphamide (PTCy) has significantly improved GVHD control, making outcomes much more comparable to those of unrelated donor transplants. Although immune reconstitution may be slower in the initial phase following a haploidentical transplant, modern conditioning and supportive care strategies have helped bridge this gap.

Current trends:

Outcomes for haploidentical transplantation have improved substantially in recent years, particularly with the routine use of post-transplant cyclophosphamide to prevent severe GVHD. Many transplant centers now consider haploidentical donors to be equivalent to matched unrelated donors when a matched sibling is not available.

Ultimately, the choice of donor and transplant approach depends on the individual clinical situation and the judgment of the transplant team. A half-matched related donor can be a strong option, especially when no fully matched donor is available, due to timely access and promising outcomes.

Recovery expectations:

Blood cell counts typically begin to recover within the first month following transplantation. If there is no significant recovery by around the third month, this may indicate graft failure, particularly in patients with a history of multiple transfusions and potential alloimmunization.

I hope this helps.

Kindly revert so I can assist you further.

Thank you.